Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AVTE | Common Stock | Conversion of derivative security | +3.94M | +1631.02% | 4.18M | Jul 2, 2021 | See footnotes | F1, F2, F5 | ||
transaction | AVTE | Common Stock | Purchase | $39M | +2.79M | +66.65% | $14.00 | 6.97M | Jul 2, 2021 | See footnotes | F2, F5 |
transaction | AVTE | Common Stock | Conversion of derivative security | +987K | 987K | Jul 2, 2021 | See footnotes | F1, F3, F5 | |||
transaction | AVTE | Common Stock | Conversion of derivative security | +311K | 311K | Jul 2, 2021 | See footnotes | F1, F4, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AVTE | Series Seed Preferred Stock | Conversion of derivative security | $0 | -4M | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 1.29M | See footnotes | F1, F2, F5 | |
transaction | AVTE | Series A Preferred Stock | Conversion of derivative security | $0 | -8.23M | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 2.65M | See footnotes | F1, F2, F5 | |
transaction | AVTE | Series A Preferred Stock | Conversion of derivative security | $0 | -3.07M | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 987K | See footnotes | F1, F3, F5 | |
transaction | AVTE | Series A Preferred Stock | Conversion of derivative security | $0 | -967K | -100% | $0.00* | 0 | Jul 2, 2021 | Common Stock | 311K | See footnotes | F1, F4, F5 |
Id | Content |
---|---|
F1 | On July 2, 2021, each share of Series Seed Preferred Stock and Series A Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-3.1060103 basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
F2 | These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). |
F3 | These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). |
F4 | These securities are held directly by a separately managed account (the "Account"). |
F5 | RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |